SPT Sulphur Polymer Technologies Inc. Acquisition of Patents and Formula for Sulstar(tm) and Sulconcrete Technology for North America - Update

February 24, 2015 1:05 PM

Vancouver, BC / ACCESSWIRE / February 24, 2015 / Further to the Company's News Release of January 27, 2015, the Company reports that it is in advanced negotiations towards a positive outcome of the acquisition announced therein. The transaction is subject to the approval of the Canadian Securities Exchange. The acquisition of the IP is also subject to completion of due diligence by the Company and a definitive agreement being...

Read more

Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions

February 18, 2015 12:42 PM

GOLDEN, CO / ACCESSWIRE / February 18, 2015 / Vitro Diagnostics, Inc. (OTCQB:VODG), DBA Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions. We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal of cell death responses to ischemic stroke by carotid...

Read more

Amooranin Preclinical Sample Batch Nears Completion

February 11, 2015 8:00 AM

LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer. "We expect the preclinical batch of methyl amooranin will be completed by the end of February, 2015," stated Gary Rojewski, CEO of EnzymeBioSystems. He...

Read more

Abattis Announces New Corporate Communications Appointment

February 4, 2015 9:03 AM

Vancouver, BC / ACCESSWIRE / February 4, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce the resignation of Saf Dhillon...

Read more

Avagenesis Corp. Appoints IR Consultant

February 3, 2015 11:51 AM

Calgary, Alberta / ACCESSWIRE / February 3, 2015 / Avagenesis Corp. (TSXV: VVA) ("Avagenesis" or the "Company"), is pleased to announce that it has retained the California-based firm of San Diego Torrey Hills Capital, Inc. ("Torrey") to conduct investor relations activities on behalf of the Company. Headed by Mr. Clifford Mastricola, Torrey is an investor and financial public relations firm specializing in introducing small-cap companies to...

Read more